Effects of Low-Dose Combination Therapy with an Angiotensin-Converting Enzyme Inhibitor and a Diuretic on Flow-Mediated Vasodilation in Hypertensive Patients: A 6-Month, Single-Center Study

Simple item page
dc.contributor.authorSekuri C.
dc.contributor.authorBayturan O.
dc.contributor.authorGocer H.
dc.contributor.authorTavli T.
dc.contributor.authorTezcan U.K.
dc.date.accessioned2024-07-22T08:24:59Z
dc.date.available2024-07-22T08:24:59Z
dc.date.issued2003
dc.description.abstractBackground: Combination therapy with an angiotensin-converting enzyme (ACE) inhibitor and a diuretic has been shown to be highly effective in hypertension. Clinical trials have demonstrated that ACE inhibitors may improve endothelial cell dysfunction in hypertension. However, the effectiveness of the combination treatment in endothelial cell dysfunction is unknown. Objective: This study investigated the effects of a new low-dose combination, perindopril 2 mg plus indapamide 0.625 mg, on brachial artery flow-mediated vasodilation (FMD) and left ventricular diastolic function in hypertension. Methods: Patients aged 18 to 75 with newly diagnosed stage 1 or 11 hypertension were eligible. Endothelium-dependent brachial artery FMD and endothelium-independent vasodilation were assessed at baseline. Patients were treated with oral perindopril 2 mg plus indapamide 0.625-mg tablets once daily for 6 months. FMD measurements were then repeated. Percentage changes in FMD from baseline to 6 months, as well as left ventricular diastolic function parameters (isovolumic relaxation time [IVRT] and mitral diastolic E-wave deceleration time [EDT]), indicated the effectiveness of the intervention. Results: Twenty-nine Turkish patients were enrolled (17 women, 12 men; mean [SD] age, 54.5 [9.5] years [range, 38-75 years]). The mean (SD) baseline FMD was 7.00% (2.39%) (endothelial cell dysfunction) and increased significantly to 8.68% (2.78%) at 6 months (P = 0.02); FMD improved in 15 patients (51.7%). At baseline and 6 months of therapy, mean (SD) IVRT was 101.7 (12.4) ms and 95.5 (7.7) ms, respectively (P < 0.001), and EDT was 234.7 (33.9) ms and 217.9 (25.6) ms, respectively (P < 0.001). Conclusions: In this small sample of hypertensive patients, a low-dose combination ACE inhibitor and diuretic significantly improved brachial artery FMD and left ventricular diastolic function. The improvement in FMD values was independent of the stage of hypertension. These findings suggest a relationship between improvement in endothelial cell function and diastolic function. Copyright © 2003 Excerpta Medica, Inc.
dc.identifier.DOI-ID10.1016/j.curtheres.2003.11.005
dc.identifier.issn0011393X
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/20215
dc.language.isoEnglish
dc.publisherExcerpta Medica Inc.
dc.rightsAll Open Access; Green Open Access
dc.subjectdipeptidyl carboxypeptidase inhibitor
dc.subjectdiuretic agent
dc.subjectindapamide
dc.subjectperindopril
dc.subjectadd on therapy
dc.subjectadult
dc.subjectaged
dc.subjectartery endothelium
dc.subjectarticle
dc.subjectbrachial artery
dc.subjectcell function
dc.subjectclinical article
dc.subjectcontrolled study
dc.subjectdiastole
dc.subjectdisease severity
dc.subjectdose response
dc.subjectdrug effect
dc.subjectdrug efficacy
dc.subjectendothelium cell
dc.subjectfemale
dc.subjectheart left ventricle filling
dc.subjectheart left ventricle function
dc.subjecthuman
dc.subjecthypertension
dc.subjectlow drug dose
dc.subjectmale
dc.subjectpriority journal
dc.subjecttreatment outcome
dc.subjectvasodilatation
dc.titleEffects of Low-Dose Combination Therapy with an Angiotensin-Converting Enzyme Inhibitor and a Diuretic on Flow-Mediated Vasodilation in Hypertensive Patients: A 6-Month, Single-Center Study
dc.typeArticle

Files

Collections

Scopus Koleksiyonu